Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Chemotherapy-Induced Nausea and Vomiting

Chemotherapy-Induced Nausea and Vomiting

8 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Chemotherapy-Induced Nausea and Vomiting

39 trials tracked for Chemotherapy-Induced Nausea and Vomiting: 19 in phase 3 or 4 and 6 with published results. The most-cited published study has 251 citations.

39Trials tracked
19Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 2 Phase 3 17 Phase 2 10 Phase 1 4 Other / NA 6
  1. Phase 3 Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting Completed · 251 cited
  2. Phase 3 A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting Completed · 40 cited
  3. Phase 3 A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting. Completed · 32 cited
  4. Phase 3 A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC Completed · 24 cited
  5. Phase 3 A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer Completed · 14 cited
  6. Phase 4 Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045) Completed
Show 33 more trials
  1. Phase 4 Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) Completed
  2. Phase 3 An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting Completed
  3. Phase 3 Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer Completed
  4. Phase 3 Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants Completed
  5. Phase 3 Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients Completed
  6. Phase 3 A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting Completed
  7. Phase 3 Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy Completed
  8. Phase 3 An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting Completed
  9. Phase 3 Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED) Completed
  10. Phase 3 Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy Completed
  11. Phase 3 A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208) Completed
  12. Phase 3 Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy Completed
  13. Phase 3 An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting Completed
  14. Phase 2 Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients Completed
  15. Phase 2 Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study Completed
  16. Phase 2 Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV) Completed
  17. Phase 2 Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy Completed
  18. Phase 2 Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting Completed
  19. Phase 2 Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting Completed
  20. Phase 2 Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029) Completed
  21. Phase 2 Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors Completed
  22. Phase 2 Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin Completed
  23. Phase 2 Use of Aromatherapy to Reduce Symptom Burden Completed
  24. Phase 1 A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165) Completed
  25. Phase 1 A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED) Completed
  26. Phase 1 A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012) Completed
  27. Phase 1 Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106) Completed
  28. N/A Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed
  29. N/A Acupuncture for Chemotherapy-Induced Nausea and Vomiting Completed
  30. N/A Observational Study on the Use of Akynzeo® in Patients Receiving HEC Completed
  31. N/A Re-examination Study of EMEND (Aprepitant) (MK-0869-184) Completed
  32. N/A Fosaprepitant in Patients Receiving Ifosfamide-based Regimen Completed
  33. N/A Promoting Cancer Symptom Management in Older Adults Completed

Showing the 39 most-cited and recently-updated of 39 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Chemotherapy-Induced Nausea and Vomiting: what the trials found

Several neurokinin-1 (NK1) receptor antagonists and combinations have demonstrated efficacy in managing chemotherapy-induced nausea and vomiting (CINV). NEPA (netupitant/palonosetron) showed a high probability of complete response over three cycles of chemotherapy (0.810) with significant results for acute, delayed, and overall CINV indicators 1. Similarly, the combination of netupitant and palonosetron demonstrated significantly higher rates of complete response at Cycle 1 compared to other treatments (74.3% vs 66.6%, p=0.001; 88.4% vs 85.0%, p=0.047) 14.

Rolapitant demonstrated significantly higher rates of complete response (no emesis and no rescue medication) compared to standard treatments in multiple trials, with results reaching statistical significance across different study populations [11, 12, 13]. Palonosetron showed high rates of complete response in both acute (186%) and delayed (170% or 165%) phases 10, while oral palonosetron also demonstrated high rates of no emesis and no rescue medication 15.

Other agents including aprepitant, casopitant, and fosaprepitant were evaluated for CINV. Aprepitant showed statistically significant improvements in complete response across acute (66.4% vs 52.0%, p<0.05), delayed (50.7% vs 26.0%, p<0.01), and overall phases 18, as well as higher numbers of patients reporting no vomiting 19. Casopitant demonstrated high rates of complete response in both acute and delayed phases for moderately emetogenic chemotherapy (MEC) regimens 5.

Olanzapine was evaluated in multiple trials, though results regarding its superiority over other medications were not statistically significant in some comparisons [3, 8, 22]. Other agents such as dexamethasone 9, fosnetupitant/palonosetron 7, and APF530 6 were also studied for CINV management.

Recent results — preliminary, needs further review

  • Essential oils were investigated for CINVR symptoms and anxiety; however, results did not reach statistical significance (p=0.462; p=0.285) 21.

For the clinician treating this condition

  • NK1 receptor antagonists like Rolapitant, Netupitant/Palonosetron, and Aprepitant have demonstrated statistically significant improvements in complete response rates for CINV.
  • Palonosetron and Casopitant show high rates of complete response in both acute and delayed phases of chemotherapy.
  • While multiple agents are available, specific combinations like NEPA show high probability of success across multiple cycles of chemotherapy.

AI synthesis of 11 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Olanzapine containing regimens consistently improve complete response across all phases of chemotherapy-induced nausea and vomiting
Oncology Sys. Review
Olanzapine containing regimens consistently improve complete response across all phases of chemotherapy-induced nausea and vomiting Olanzapine helps manage nausea and vomiting during chemotherapy treatment
This network meta-analysis of 10,455 adults receiving chemotherapy found that olanzapine-containing regimens consistently improved complete …
New data shows olanzapine can effectively control nausea and vomiting for patients undergoing chemotherapy, with lower doses showing similar…
Jul 17, 2026
Olanzapine significantly improves complete response and total control in chemotherapy-induced nausea for breast cancer
Oncology Meta-analysis
Olanzapine significantly improves complete response and total control in chemotherapy-induced nausea for breast cancer Olanzapine helps manage nausea in breast cancer chemotherapy
This meta-analysis of 4 studies involving 857 patients found that olanzapine with regular antiemetic treatment improved complete response (R…
Adding olanzapine to standard care can significantly improve nausea control and complete response for patients undergoing breast cancer chem…
Jun 17, 2026
Meta-analysis of 12 studies reports chemotherapy-induced nausea and vomiting prevalence and risk factors in breast cancer patients
Oncology Meta-analysis
Meta-analysis of 12 studies reports chemotherapy-induced nausea and vomiting prevalence and risk factors in breast cancer patients Nearly Half of Breast Cancer Patients Face This Rough Side Effect
This meta-analysis pooled data from 12 studies involving breast cancer patients undergoing chemotherapy to assess the prevalence of chemothe…
Knowing who is most likely to get sick from chemo allows doctors to step in before nausea takes over a patient's life.
Apr 13, 2026
Electronic antiemetic device plus ondansetron improved delayed CINV response in 126 cancer patients
Oncology RCT
Electronic antiemetic device plus ondansetron improved delayed CINV response in 126 cancer patients A Wearable Buzz on Your Wrist May Ease Chemo Nausea
This single-centre randomized controlled trial enrolled 126 cancer patients receiving moderately or highly emetogenic chemotherapy.
A small device targeting an old acupressure point may give real relief from the days-long nausea that chemo drugs leave behind.
Apr 13, 2026
FDA Approves Ondansetron Injection, USP (ondansetron hydrochloride) for Prevention of Chemotherapy-Induced and Postoperative Nausea/Vomiting
Oncology FDA Approval
FDA Approves Ondansetron Injection, USP (ondansetron hydrochloride) for Prevention of Chemotherapy-Induced and Postoperative Nausea/Vomiting FDA approves a new preservative-free injection to prevent nausea and vomiting from chemotherapy and surgery
FDA approved ondansetron injection for prevention of nausea/vomiting associated with emetogenic cancer chemotherapy and postoperative nausea…
FDA approves a new preservative-free injection to prevent nausea and vomiting from chemotherapy and surgery.
FDA Apr 10, 2026
Network meta-analysis compares 5-HT3 antagonists with or without dexamethasone for highly emetogenic chemotherapy-induced nausea and vomiting
Oncology Meta-analysis
Network meta-analysis compares 5-HT3 antagonists with or without dexamethasone for highly emetogenic chemotherapy-induced nausea and vomiting New analysis suggests palonosetron plus dexamethasone may reduce delayed vomiting in chemotherapy patients
This network meta-analysis evaluated 5-hydroxytryptamine-3 (5-HT3) receptor antagonists with or without dexamethasone in patients undergoing…
Combining palonosetron with dexamethasone reduces delayed vomiting in chemotherapy patients better than other common drug options.
Apr 9, 2026
FDA Approves Focinvez (fosaprepitant) for Prevention of Chemotherapy-Induced Nausea and Vomiting
Oncology FDA Approval
FDA Approves Focinvez (fosaprepitant) for Prevention of Chemotherapy-Induced Nausea and Vomiting FDA approves a new intravenous drug to help prevent nausea and vomiting from chemotherapy
The FDA has approved Focinvez, a substance P/NK1 receptor antagonist, for the prevention of acute and delayed nausea and vomiting associated…
FDA approves new IV drug to prevent severe nausea and vomiting from chemotherapy in adults and children 6 months and older.
FDA Apr 2, 2026
FDA Approves Marinol (dronabinol) for AIDS-Related Anorexia and Chemotherapy-Induced Nausea/Vomiting
Oncology FDA Approval
FDA Approves Marinol (dronabinol) for AIDS-Related Anorexia and Chemotherapy-Induced Nausea/Vomiting FDA approves a new drug called Marinol to help with AIDS-related weight loss and chemotherapy nausea
The FDA has approved Marinol (dronabinol) for two indications in adults: anorexia associated with weight loss in patients with AIDS, and nau…
The FDA approved Marinol to treat AIDS-related weight loss and severe chemotherapy nausea that standard treatments couldn't control.
FDA Mar 31, 2026

Questions about Chemotherapy-Induced Nausea and Vomiting

What risk factors are associated with chemotherapy-induced nausea and vomiting in breast cancer?

Key risk factors for CINV in breast cancer include younger age (≤45 years), history of motion sickness, and multiple chemotherapy cycles (≥3).

Full answer →
Can Focinvez prevent chemotherapy-induced nausea and vomiting in cancer patients?

Yes, Focinvez (fosaprepitant) is FDA-approved to prevent chemotherapy-induced nausea and vomiting when used with other antiemetics.

Full answer →
How do 5-HT3 antagonists compare to dexamethasone for highly emetogenic chemotherapy-induced nausea and vomiting?

5-HT3 antagonists and dexamethasone are both effective for CINV, but adding a 5-HT3 antagonist to dexamethasone improves outcomes; guidelines recommend using them together with other agents for highly emetogenic chemotherapy.

Full answer →
How common is chemotherapy-induced nausea and vomiting in breast cancer patients?

About 48% of breast cancer patients experience chemotherapy-induced nausea and vomiting, with higher risk in younger patients and those with motion sickness history.

Full answer →